Comments
Zydus Cadila has received tentative approval from the US health regulator to market Sitagliptin tablets, indicated for treating diabetes, in the American market.
The company has received tentative approval from the United States Food and Drug Administration (USFDA) to market Sitagliptin tablets in strengths of 25 mg, 50 mg, and 100 mg, Zydus Cadila said in a BSE filing today.
The filing said that the drug will be produced at the group’s formulations facility at SEZ, Ahmedabad. The group has more than 217 approvals, and so far filed over 330 abbreviated new drug applications (ANDAs).
Shares of Cadila Healthcare, the listed entity of the group, were trading down by 0.59 per cent at Rs 418.30 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.